Computational Design and Preliminary Serological Analysis of a Novel Multi-Epitope Vaccine Candidate against Onchocerciasis and Related Filarial Diseases

Robert Adamu Shey, Stephen Mbigha Ghogomu, Cabirou Mounchili Shintouo, Francis Nongley Nkemngo, Derrick Neba Nebangwa, Kevin Esoh, Ntang Emmaculate Yaah, Muyanui Manka'aFri, Joel Ebai Nguve, Roland Akwelle Ngwese, Ferdinand Ngale Njume, Fru Asa Bertha, Lawrence Ayong, Rose Njemini, Luc Vanhamme, Jacob Souopgui

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)


: Onchocerciasis is a skin and eye disease that exerts a heavy socio-economic burden, particularly in sub-Saharan Africa, a region which harbours greater than 96% of either infected or at-risk populations. The elimination plan for the disease is currently challenged by many factors including amongst others; the potential emergence of resistance to the main chemotherapeutic agent, ivermectin (IVM). Novel tools, including preventative and therapeutic vaccines, could provide additional impetus to the disease elimination tool portfolio. Several observations in both humans and animals have provided evidence for the development of both natural and artificial acquired immunity. In this study, immuno-informatics tools were applied to design a filarial-conserved multi-epitope subunit vaccine candidate, (designated Ov-DKR-2) consisting of B-and T-lymphocyte epitopes of eight immunogenic antigens previously assessed in pre-clinical studies. The high-percentage conservation of the selected proteins and epitopes predicted in related nematode parasitic species hints that the generated chimera may be instrumental for cross-protection. Bioinformatics analyses were employed for the prediction, refinement, and validation of the 3D structure of the Ov-DKR-2 chimera. In-silico immune simulation projected significantly high levels of IgG1, T-helper, T-cytotoxic cells, INF-γ, and IL-2 responses. Preliminary immunological analyses revealed that the multi-epitope vaccine candidate reacted with antibodies in sera from both onchocerciasis-infected individuals, endemic normals as well as loiasis-infected persons but not with the control sera from European individuals. These results support the premise for further characterisation of the engineered protein as a vaccine candidate for onchocerciasis.

Original languageEnglish
Article number99
Pages (from-to)1-32
Number of pages32
JournalPLoS Pathogens
Issue number2
Publication statusPublished - Feb 2021


  • IgG
  • Onchocerca volvulus
  • Ov-DKR-2
  • chimeric antigen
  • vaccine development


Dive into the research topics of 'Computational Design and Preliminary Serological Analysis of a Novel Multi-Epitope Vaccine Candidate against Onchocerciasis and Related Filarial Diseases'. Together they form a unique fingerprint.

Cite this